<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Werner syndrome
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Werner syndrome
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Werner syndrome
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Raymond J Monnat, Jr, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Fuki M Hisama, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jennifer L Hand, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Rosamaria Corona, MD, DSc
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 27, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H3020800072">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Werner syndrome (WS; MIM #277700), also known as adult progeria, is a rare, autosomal recessive, progeroid (premature aging-like) syndrome caused by loss-of-function variants of the
         <em>
          WRN
         </em>
         gene on chromosome 8p12 [
         <a href="#rid1">
          1,2
         </a>
         ]. WS is characterized by short stature and signs of premature aging in young or middle-aged adults, including early graying and loss of hair, bilateral cataracts, and scleroderma-like skin changes (
         <a class="graphic graphic_picture graphicRef132645" href="/z/d/graphic/132645.html" rel="external">
          picture 1
         </a>
         ). These changes are accompanied by an elevated risk of clinically important, age-associated diseases, including cardiovascular disease, diabetes mellitus, and osteoporosis. Moreover, patients with WS have an elevated risk of several different types of cancer.
        </p>
        <p>
         This topic will discuss the genetics, pathogenesis, diagnosis, and management of WS. Atypical WS and several other rare, progeroid syndromes will also be briefly discussed here [
         <a href="#rid2">
          2
         </a>
         ]. Hutchinson-Gilford progeria syndrome (HGPS) is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/106741.html" rel="external">
          "Hutchinson-Gilford progeria syndrome"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3973390257">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Individuals with Werner syndrome (WS) have been reported worldwide. Males and females are diagnosed in equal numbers. The estimated incidence ranges from &lt;1 per 100,000 births to 1 per 10,000. Geographic case and family clusters of WS often reflect local founder pathogenic variants of
         <em>
          WRN
         </em>
         and have been reported in Japan, Sardinia, India, and Pakistan [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         In a study of 9019 individuals from the combined Exome Sequencing Project/1000 Genomes Project datasets designed to capture genetic variation in geographic and ancestrally diverse populations, the pathogenic
         <em>
          WRN
         </em>
         allele carrier frequency was estimated to be approximately 2 percent [
         <a href="#rid4">
          4
         </a>
         ]. Carriers were virtually all heterozygotes, with the exception of four putative homozygous individuals [
         <a href="#rid4">
          4
         </a>
         ]. This high population prevalence of known pathogenic
         <em>
          WRN
         </em>
         variants, despite the apparent rarity of WS, supports the hypothesis that WS is clinically under-recognized and underdiagnosed.
        </p>
        <p class="headingAnchor" id="H384382966">
         <span class="h1">
          PATHOPHYSIOLOGY
         </span>
        </p>
        <p class="headingAnchor" id="H2607528760">
         <span class="h2">
          Inheritance and molecular genetics
         </span>
         <span class="headingEndMark">
          —
         </span>
         Werner syndrome (WS) is an autosomal recessive disorder caused by pathogenic loss-of-function variants of the
         <em>
          WRN
         </em>
         gene on chromosome 8p12. Positional cloning and analysis revealed that
         <em>
          WRN
         </em>
         is a 145 kb gene consisting of 35 exons that encode a 1432 amino acid protein with ATPase, 3'-5'
         <strong>
         </strong>
         helicase, and 3'-5' exonuclease activities [
         <a href="#rid5">
          5
         </a>
         ]. Presence of the deeply conserved helicase domain led to identification of
         <em>
          WRN
         </em>
         as one of five human
         <em>
          RECQ
         </em>
         helicase genes. Loss of function of two other human
         <em>
          RECQ
         </em>
         helicases,
         <em>
          BLM
         </em>
         and
         <em>
          RECQL4
         </em>
         , have been linked, respectively, to two other cancer predisposition syndromes: Bloom syndrome and Rothmund-Thomson syndrome [
         <a href="#rid6">
          6
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3959.html" rel="external">
          "Bloom syndrome"
         </a>
         .)
        </p>
        <p>
         The human
         <em>
          WRN
         </em>
         gene displays abundant genetic variation. Nearly 2300 sequence variants in or within 75 base pairs of a
         <em>
          WRN
         </em>
         coding exon were identified in 125,748 exome sequences and 15,708 whole genome sequences from unrelated individuals [
         <a href="#rid7">
          7
         </a>
         ]. The most common pathogenic
         <em>
          WRN
         </em>
         variant is a nonsense mutation in exon 8 (c.1105C&gt;T, rs17847577, p.R369*), which accounts for approximately 20 percent of pathogenic alleles, with a frequency of 1.8 to 3.0 per 10,000 in The Genome Aggregation Database (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fgnomad.broadinstitute.org%2F&amp;token=SJGIfO8IYUzQ845m1rgVQYdPlYK0%2F7aVbl4RfdLyOSvBEOxGd6ZNcsqpBwtjw%2F6S&amp;TOPIC_ID=106742" target="_blank">
          gnomAD
         </a>
         ) [
         <a href="#rid7">
          7,8
         </a>
         ]. One Japanese pathogenic variant (c.3139-1G&gt;C, leading to an exon 26 skip) accounts for approximately 70 percent of the mutant alleles identified in patients with WS in Japan, where the aggregate carrier frequency for pathogenic variants is estimated to be 1 in 167 [
         <a href="#rid5">
          5,9,10
         </a>
         ]. Other common pathogenic variants include c.2089-3024A&gt;G (which alters splicing with the inclusion of a new exon between exons 18 and 19) in Sardinian patients with WS, with a reported frequency of approximately 1 in 120 [
         <a href="#rid11">
          11
         </a>
         ]; c.561A&gt;G (which alters exon 6 splicing) in patients with WS of Indian/Pakistani ancestry; and c.3460-2A&gt;G (leading to exon 30 skipping) identified in patients with WS of Turkish ancestry [
         <a href="#rid3">
          3,12
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1323709565">
         <span class="h2">
          Functions of the WRN protein
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          WRN
         </em>
         gene and protein expression are ubiquitous, though the tissue and cell type-specific expression during development or adult lifespan is not known [
         <a href="#rid1">
          1,6
         </a>
         ].
        </p>
        <p>
         The WRN helicase belongs to a DEAH-box-containing RecQ family of helicases. It is involved in the repair of potentially deleterious deoxyribonucleic acid (DNA) structures, such as branched intermediates formed during DNA replication, recombination, and transcription, and sequence-dependent structures, such as G-quadruplex DNA and the telomere "caps" that protect chromosome ends [
         <a href="#rid1">
          1,13,14
         </a>
         ]. These DNA structures may disrupt DNA metabolism and trigger cell cycle arrest or death if not appropriately handled during cell replication and division.
        </p>
        <p>
         WRN is unique among the human RECQ helicase proteins in possessing a 3'-5' exonuclease activity in addition to ATPase and helicase activities. Other WRN protein domains include a C-terminal nuclear localization signal (NLS) and RECQ conserved/consensus (RQC) and helicase, RNaseD, C-terminal conserved region (HRDC) domains, which play roles in substrate DNA binding and WRN recruitment to DNA double-strand breaks, respectively. The WRN protein also possesses single-strand DNA annealing activity.
        </p>
        <p>
         Virtually all of the clinically ascertained
         <em>
          WRN
         </em>
         variants mentioned above confer a common biochemical phenotype: loss of the WRN protein together with helicase, ATPase, and exonuclease activities [
         <a href="#rid15">
          15
         </a>
         ]. Experimental data and the absence of clinically ascertained variants that selectively eliminate a single WRN catalytic activity indicate that WS pathogenesis requires the loss of all WRN-associated catalytic activities from patient cells [
         <a href="#rid16">
          16
         </a>
         ]. This idea is reinforced by an analysis of individuals homozygous for a WRN missense variant, p.R834C, that largely abolishes WRN helicase activity, preserves WRN-associated catalytic activity, but does not confer a WS clinical phenotype [
         <a href="#rid17">
          17,18
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H940194742">
         <span class="h2">
          WRN helicase and cancer
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with WS have an increased risk of developing several specific types of cancer (
         <a class="graphic graphic_table graphicRef132650" href="/z/d/graphic/132650.html" rel="external">
          table 1
         </a>
         ). Only a few of the neoplasms arising in patients with WS have been molecularly characterized, and therefore, it is not known whether they have unique or defining genomic features [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p>
         The loss of WRN function in the presence of a mismatch repair (MMR) deficiency confers a strong cell-lethal phenotype. This observation is of high conceptual and practical interest. It predicts that patients with WS are protected against cancers associated with MMR deficiency, such as colorectal cancer [
         <a href="#rid20">
          20-23
         </a>
         ], and has generated considerable interest in developing small molecule inhibitors of WRN catalytic activities as a novel way to treat MMR-deficient cancers in the general population [
         <a href="#rid24">
          24,25
         </a>
         ]. MMR-deficient cancers include subsets of common adult epithelial malignancies, such as colorectal, gastric, and endometrial carcinomas [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2829473625">
         <span class="h1">
          CLINICAL FEATURES
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical phenotype of Werner syndrome (WS) is often first expressed and clinically discernable in adolescence or early adulthood. This is in contrast with nearly all other progeroid syndromes that have strongly penetrant phenotypes in infancy or early childhood (see
         <a class="medical medical_review" href="/z/d/html/106741.html" rel="external">
          "Hutchinson-Gilford progeria syndrome"
         </a>
         ). The delayed initial appearance and continued clinical progression spanning over several decades can be readily appreciated in pairs of photos taken of patients with WS when they were teenagers, then later in their 40s or 50s (
         <a class="graphic graphic_picture graphicRef132645" href="/z/d/graphic/132645.html" rel="external">
          picture 1
         </a>
         ) [
         <a href="#rid1">
          1,27-31
         </a>
         ].
        </p>
        <p>
         Clinical signs that develop in virtually all patients with WS and referred to as cardinal signs of WS include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Short
         </strong>
         <strong>
          stature
         </strong>
         – Short stature, due to lack of a growth spurt during adolescence, is often the first sign of WS.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cataracts
         </strong>
         – Most patients develop bilateral cataracts by the second or third decade of life. The cataracts are predominantly posterior cortical and subcapsular, with less frequent vacuolization and small, punctate opacities in other parts of the lens. This type of cataract, often referred to as "juvenile," is distinct from the nuclear opacities commonly observed in the "senile" cataracts occurring in older individuals without WS.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Graying and loss of hair
         </strong>
         – Early graying and hair loss are, together with short stature, among the earliest and most consistent findings in patients with WS. They start in the second decade of life and first affect the scalp and eyebrows. The loss of hair pigmentation is progressive and may eventually be complete. Similar changes occur in body hair but usually start later and may not be as extensive as those observed in the scalp and eyebrows.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Scleroderma-like skin changes
         </strong>
         – Scleroderma-like skin changes are often first noted in the face and extremities and lead to a progressive sharpening of facial features, with many patients eventually developing a "pinched," "beaked," or "bird-like" appearance. Lower extremities, especially the feet, are often affected with foot deformation and flattening, ulceration of non-pressure-bearing portions of the foot and ankles (
         <a class="graphic graphic_picture graphicRef132648" href="/z/d/graphic/132648.html" rel="external">
          picture 2
         </a>
         ), and a characteristic calcification of soft tissue and tendons (
         <a class="graphic graphic_diagnosticimage graphicRef133224" href="/z/d/graphic/133224.html" rel="external">
          image 1
         </a>
         )
         <strong>
         </strong>
         [
         <a href="#rid32">
          32-34
         </a>
         ]. Indolent foot and ankle ulcers are highly characteristic of WS and a significant source of morbidity.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Skin biopsies reveal epidermal atrophy extending into the skin appendages (hair follicles, sweat glands, and sebaceous glands), in conjunction with focal hyperkeratosis and basal hypermelanosis. Dermal, subcutaneous connective tissue atrophy is common, often in conjunction with dermal fibrosis and atrophy of underlying adipose, connective, and muscle tissue [
         <a href="#rid28">
          28,32
         </a>
         ]. This constellation of changes gives skin a "tight and shiny" appearance, with loss of normal elasticity.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          High-pitched, hoarse voice
         </strong>
         – A thin, high-pitched voice is characteristic and results from proliferative and atrophic, laryngeal changes.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other prominent clinical features
         </strong>
         – These include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Atherosclerosis and its cardiovascular and cerebral vascular sequelae
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Osteoporosis, which is typically most severe in the distal phalanges of the extremities
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Diabetes mellitus
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hypogonadism and declining fertility affecting males and females
        </p>
        <p>
        </p>
        <p>
         Age-associated, neurodegenerative diseases, such as Alzheimer disease and Parkinson disease, do not appear to be more prevalent among patients with WS, including those who live into their sixth or seventh decade.
        </p>
        <p class="headingAnchor" id="H990530909">
         <span class="h1">
          CLINICAL COURSE
         </span>
         <span class="headingEndMark">
          —
         </span>
         One aspect of Werner syndrome (WS) not well appreciated from the list of diagnostic findings (
         <a class="graphic graphic_table graphicRef132672" href="/z/d/graphic/132672.html" rel="external">
          table 2
         </a>
         ) is the progressive nature of WS. Full expression with the eventual appearance of the canonical features of WS may appear only two or three decades after an initial diagnosis in the second decade of life. A sense of this progressive expression of findings is readily apparent from pairs of patient photos taken in early adulthood and later in midlife (
         <a class="graphic graphic_picture graphicRef132645" href="/z/d/graphic/132645.html" rel="external">
          picture 1
         </a>
         ).
        </p>
        <p>
         This phenotypic progression of WS can be usefully described as three overlapping phases:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The first phase is the absence of an adolescent growth spurt, followed over the subsequent decade by the appearance of graying and loss of hair and development of skin changes and cataracts. Indeed, prior to puberty, many patients with WS display no signs characteristic of WS.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A second phase, often first seen late in the third decade, includes skin ulceration, hypogonadism, and infertility together with further progression of primary changes. Both females and males with WS have been reported as having biologic children, although generally at younger ages.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A third phase includes a rapidly rising risk of age-associated diseases, such as atherosclerosis, osteoporosis, diabetes mellitus, and cancer. These complications develop earlier or are more severe in patients with WS than in age- and sex-matched control individuals. Deep, chronic ulcerations of the medial or lateral malleolus or the Achilles tendon, ubiquitous in patients of Japanese ancestry and frequently noted in individuals of other ancestries with WS, are a major source of morbidity in many patients [
         <a href="#rid33">
          33,34
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H181413459">
         <span class="h1">
          RISK OF CANCER
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with Werner syndrome (WS) are at increased risk of developing cancer, and cancer remains a leading cause of premature morbidity and death among individuals with WS. A systematic review of published cases of WS that included 139 patients from Japan and 50 patients of diverse ethnicities and locations reported between 1939 and 2011 found that six types of cancer (thyroid epithelial neoplasms, melanoma, meningiomas, soft tissue sarcomas, leukemia and preleukemic conditions, and primary bone neoplasms) represented two-thirds of all cancers reported in WS (
         <a class="graphic graphic_table graphicRef132650" href="/z/d/graphic/132650.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p>
         In Japanese patients, the cancer standardized incidence ratio (SIR) relative to the general population ranged from 8.9 for thyroid neoplasms (95% CI 4.9-15.0) to 53.5 for melanoma (95% CI 24.5-101.6). No good model exists to explain why or how the incidence of these specific neoplasms is elevated in patients with WS. Diabetes mellitus, a common feature of WS, may confer a higher general risk of cancer; however, this hypothesis is disputed [
         <a href="#rid36">
          36,37
         </a>
         ].
        </p>
        <p>
         The development of cancer at an early age, at unusual sites (eg, osteosarcoma of the patella), or with less common histopathologic subtypes (eg, follicular, as opposed to the more common papillary, thyroid carcinoma) may raise an initial suspicion of WS. These atypical or unusual clinical presentations are a feature of many other cancer predisposition syndromes.
        </p>
        <p>
         Melanomas in WS are, in most cases, acral lentiginous melanomas and mucosal involving the nasal or esophageal mucosa [
         <a href="#rid35">
          35,38
         </a>
         ]. The elevated risk of acral lentiginous melanoma in Japanese patients with WS suggests a potential role for population-specific risk modifiers.
        </p>
        <p>
         Multiple neoplasms are remarkably common in WS. Up to five different primary neoplasms have been reported in individual patients, and nearly one-quarter of patients have two or more histologically distinct types of cancer [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p>
         Knowledge of the histopathologic spectrum of neoplasia in WS and the potential for unusual presentations or features can guide cancer surveillance in individuals with WS. (See
         <a class="local">
          'Prevention of complications'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H4240099943">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The adult onset and slow development of clinical signs and symptoms make the clinical diagnosis of Werner syndrome (WS) challenging. The definitive diagnosis is often delayed, especially in young adults who may show only a few findings. This diagnostic "lag" is often accentuated in the absence of a family history [
         <a href="#rid2">
          2,39
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical suspicion
         </strong>
         – A diagnostic suspicion of WS is often driven by considering the clinical findings in light of patient age (see
         <a class="local">
          'Clinical features'
         </a>
         above). Although the family history is usually negative, the presence of affected siblings or parental consanguinity should increase suspicion of WS. Patient ancestry is also important to note, as many patients with WS with Japan, Syria, Sardinia, and Turkey as countries of residence and/or ancestry carry common pathogenic founder alleles of
         <em>
          WRN
         </em>
         . Parental consanguinity increases the risk of rare, recessive conditions in general and, more specifically, increases the likelihood of identity by descent at the
         <em>
          WRN
         </em>
         locus.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnostic criteria
         </strong>
         – Key clinical or "cardinal" findings are eventually observed in nearly all patients with WS and have been used to develop clinical diagnostic criteria for WS. Two sets of diagnostic criteria for WS, which combine cardinal and additional findings to establish a clinical diagnosis, have been developed by the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdlmp.uw.edu%2Fresearch-center%2Fwerner%2Fregistry%2Fregistry.html&amp;token=zpNCX14A2R12bA0oIWem40juL9ratCrV9tXnJsNS8hqHuegyQFRcMHAS6777cZiW%2BEk8X9q8XiI1DeTPWXUQaa8AtSQsFLDSFqHlsS1NKKs%3D&amp;TOPIC_ID=106742" target="_blank">
          International Registry of Werner Syndrome
         </a>
         and the Japanese Werner Syndrome Registry (
         <a class="graphic graphic_table graphicRef132672" href="/z/d/graphic/132672.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid2">
          2,40
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Cardinal signs of WS include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Premature graying and/or thinning of scalp hair
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Bilateral cataract
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Scleroderma-like skin changes, intractable lower leg skin ulcers
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Soft tissue calcification (most often Achilles tendon)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Bird-like face
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         High-pitched voice
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Genetic testing
         </strong>
         – The identification of causative pathogenic variants in both copies of
         <em>
          WRN
         </em>
         can be used to confirm the diagnosis.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1379514587">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most likely clinical syndromes that may be mistaken for Werner syndrome (WS) include atypical WS, MDPL (mandibular hypoplasia, deafness, progeroid features, and lipodystrophy) syndrome, mandibuloacral dysplasia, and Hutchinson-Gilford progeria syndrome (HGPS).
        </p>
        <p class="headingAnchor" id="H3402778705">
         <span class="h2">
          Atypical Werner syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with atypical WS may resemble patients with classical WS, but the age of onset is often earlier, and clinical progression may be more rapid. Approximately 15 percent of patients have heterozygous, pathogenic, missense variants in
         <em>
          LMNA
         </em>
         ,
         <em>
         </em>
         the gene encoding lamin A [
         <a href="#rid27">
          27,41
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2701189679">
         <span class="h2">
          MDPL syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         MDPL (mandibular hypoplasia, deafness, progeroid features, and lipodystrophy) syndrome (MIM #615381) is an autosomal dominant disorder characterized by progeroid features, lipodystrophy, and sensorineural hearing loss with characteristic facial features. In contrast with WS, it is not associated with ocular cataracts or elevated risk of neoplasia. MDPL syndrome is caused by de novo, heterozygous, pathogenic variants in the
         <em>
          POLD1
         </em>
         subunit of one of the major human replicative DNA polymerases [
         <a href="#rid42">
          42,43
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1044257213">
         <span class="h2">
          Mandibuloacral dysplasia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Mandibuloacral dysplasia with type A lipodystrophy (MADA; MIM #248370) is a progeroid syndrome characterized by short stature; loss of fat in the extremities but accumulation of fat in the neck and trunk; thin, hyperpigmented skin; partial alopecia; prominent eyes; a convex nasal ridge; tooth loss, micrognathia, and retrognathia; and short fingers. MADA is caused by biallelic, pathogenic variants in
         <em>
          LMNA
         </em>
         [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p>
         Mandibuloacral dysplasia with type B lipodystrophy (MADB; MIM #608612) is associated with a generalized loss of subcutaneous fat and insulin resistance. MADB has been attributed to biallelic, pathogenic variants in the zinc metalloproteinase gene
         <em>
          ZMPSTE24
         </em>
         [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4286204587">
         <span class="h2">
          Hutchinson-Gilford progeria syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hutchinson-Gilford progeria syndrome (HGPS; MIM #176670), also known as "progeria of childhood," is a multisystem disorder with accelerated aging in the first few years of life after a profound failure to thrive during the first year. Characteristic facies, partial alopecia progressing to total alopecia, loss of subcutaneous fat, progressive joint contractures, bone changes, and abnormal tightness and/or small, soft outpouchings of the skin over the abdomen and upper thighs usually become apparent from the second year of life. Motor and mental development is normal. Individuals with HGPS develop severe atherosclerosis, with cardiac or cerebrovascular disease beginning as early as age six. The average lifespan of individuals with HGPS is approximately 15 years, and death usually occurs as a result of cardiovascular complications [
         <a href="#rid46">
          46
         </a>
         ]. Classic HGPS is caused by the single nucleotide substitution c.1824C&gt;T in the lamin A/C gene
         <em>
          LMNA
         </em>
         . Nearly all well-documented patients with HGPS carry this de novo, autosomal dominant, pathogenic variant [
         <a href="#rid47">
          47
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/106741.html" rel="external">
          "Hutchinson-Gilford progeria syndrome"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4052857722">
         <span class="h2">
          Other hereditary and acquired syndromes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several syndromes share features with WS, though they can be distinguished from WS by age of onset.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Flynn-Aird syndrome
         </strong>
         – Flynn-Aird syndrome is a neuroectodermal syndrome presenting with cataracts, skin atrophy and ulceration, and neurologic abnormalities [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Branchio-oculo-facial syndrome
         </strong>
         – Branchio-oculo-facial syndrome (BOFS; MIM #113620) is a rare, autosomal dominant disorder characterized by premature graying of the hair in adults in conjunction with strabismus, coloboma and microphthalmia, and variable dysmorphic facial features. BOFS is caused by pathogenic variants in
         <em>
          TFAP2A
         </em>
         , encoding the AP-2-alpha transcription factor [
         <a href="#rid49">
          49
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          SHORT syndrome
         </strong>
         – Features of SHORT (short stature, hyperextensibility, hernia, ocular depression, Rieger anomaly, and teething delay; MIM #269880) syndrome may include progeria-like facies, lipodystrophy, type 2 diabetes mellitus, cataracts, and glaucoma. Pathogenic variants in the
         <em>
          PIK3R1
         </em>
         gene have been identified as causal variants for this autosomal dominant disorder [
         <a href="#rid50">
          50
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1788.html" rel="external">
          "Lipodystrophic syndromes", section on 'Other syndromes with a component of lipodystrophy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Early-onset type 2 diabetes
         </strong>
         – Early-onset type 2 diabetes mellitus with secondary cardiovascular and cutaneous complications may suggest WS, but it should be easily distinguished based on other clinical features and patient history. (See
         <a class="medical medical_review" href="/z/d/html/5820.html" rel="external">
          "Epidemiology, presentation, and diagnosis of type 2 diabetes mellitus in children and adolescents"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Myotonic dystrophy type 1 or 2
         </strong>
         – Myotonic dystrophy type 1 (MIM #160900) and myotonic dystrophy type 2 (MIM #602668) should be considered in young individuals with adult-type cataracts as well as in adults with muscle wasting. However, the cataracts in WS are most often posterior subcapsular, and other features of myotonic dystrophies (eg, myotonia or cardiac conduction abnormalities) are quite different from WS, although they may appear first in adulthood. (See
         <a class="medical medical_review" href="/z/d/html/5147.html" rel="external">
          "Myotonic dystrophy: Etiology, clinical features, and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Scleroderma, mixed connective tissue disorders, and lipodystrophy
         </strong>
         – These conditions may have skin changes, including distal atrophy and skin ulcerations, that could be mistaken for WS. (See
         <a class="medical medical_review" href="/z/d/html/7539.html" rel="external">
          "Clinical manifestations and diagnosis of systemic sclerosis (scleroderma) in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7546.html" rel="external">
          "Mixed connective tissue disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1788.html" rel="external">
          "Lipodystrophic syndromes"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3755229661">
         <span class="h2">
          Other cancer-prone syndromes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Clinical features of neoplasia in WS (early age of onset, unusual histopathologic type or subtype, atypical anatomical locations) are often observed in other cancer predisposition syndromes [
         <a href="#rid51">
          51
         </a>
         ]. Cancer predisposition syndromes that can be distinguished from WS by clinical findings and molecular diagnostic test data include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Rothmund-Thomson syndrome and Bloom syndrome
         </strong>
         – These two other RECQ helicase deficiency syndromes are caused by pathogenic variants in the
         <em>
          RECQL4
         </em>
         and
         <em>
          BLM
         </em>
         genes, respectively [
         <a href="#rid52">
          52
         </a>
         ]. They can be distinguished from WS on the basis of age of onset, differing clinical findings, and genetic test results. Rothmund-Thomson syndrome is characterized by poikiloderma, short stature, skeletal and dental abnormalities, juvenile cataracts, and an increased risk for cancer, especially osteosarcoma and skin cancers. Bloom syndrome is characterized by short stature, characteristic facies, and often a sun-sensitive facial "butterfly" skin rash. (See
         <a class="medical medical_review" href="/z/d/html/3959.html" rel="external">
          "Bloom syndrome"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Li-Fraumeni syndrome
         </strong>
         – Li-Fraumeni syndrome is caused by germline, pathogenic variants in the
         <em>
          TP53
         </em>
         tumor suppressor gene and is linked to an elevated risk of several cancers, including nonepithelial cancers similar to those observed in WS. Other prominent features of WS, such as cataracts, are not part of Li-Fraumeni syndrome. (See
         <a class="medical medical_review" href="/z/d/html/14255.html" rel="external">
          "Li-Fraumeni syndrome"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3516629275">
         <span class="h1">
          MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is no specific or effective therapy for Werner syndrome (WS). Because of the multisystem nature of WS, patients should be managed in medical centers with expertise in rare, complex diseases and ready access to multiple specialty consultation, including medical genetics, ophthalmology, cardiology, dermatology, and oncology.
        </p>
        <p>
         Patients with WS are responsive to common therapeutic interventions, such as pharmacologic management of hypertension, diabetes mellitus, and lipid metabolic abnormalities; surgical removal of cataracts; and screening for cancer or other acquired diseases. Effective screening and management of these associated diseases, together with aggressive treatment of foot, ankle, and elbow ulcers, have the potential to substantially extend longevity and the quality of life for many patients [
         <a href="#rid33">
          33,34,53
         </a>
         ].
        </p>
        <p>
         Guidelines based on expert opinion for the management of diabetes mellitus, hyperlipidemia, skin ulceration, tendon calcification, infection control, and sarcopenia associated with WS have been published [
         <a href="#rid33">
          33,34,54-58
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H596454091">
         <span class="h2">
          Baseline evaluation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Once a diagnosis of WS is established, a baseline assessment should be performed to collect biometric and clinical laboratory data. This will also be an opportunity to initiate screening to identify or exclude common associated disease, including diabetes mellitus or impaired glucose tolerance; hyperlipidemia; hypertension; osteoporosis; skin changes, especially at locations prone to ulceration; and neoplasia. A family history should be taken to assess whether other relatives may be affected and to identify likely heterozygous carriers of a pathogenic
         <em>
          WRN
         </em>
         variant. In a patient with a diagnosis of WS, the initial evaluation to establish the extent of disease and make a management plan includes:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Physical examination for signs and symptoms of cardiovascular disease, cerebrovascular disease, or cancer types that are common and/or occur at elevated risk in WS (eg, thyroid nodules).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Total body skin examination, focused on early detection of foot and ankle ulceration, nail bed and foot sole acral lentiginous melanomas, and soft tissue calcification.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Type 2 diabetes mellitus screening, including determinations of fasting glucose level, hemoglobin A1C level, and/or an oral glucose tolerance test. (See
         <a class="medical medical_review" href="/z/d/html/1761.html" rel="external">
          "Screening for type 2 diabetes mellitus"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lipid panel profiling.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ophthalmologic examination, including slit lamp examination for cataract detection. Vision can be restored by cataract removal, although the risk of cystic macular edema as a postsurgical complication may be higher in patients with WS [
         <a href="#rid59">
          59
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dual-energy x-ray absorptiometry scan to evaluate for osteopenia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Subfertility or infertility can be assessed in females by inquiring about menstrual cycles and measurement of follicle-stimulating hormone (FSH) and luteinizing hormone (LH), and in males by semen analysis. Males and females with WS who plan to have children benefit from referral to a reproductive endocrinology infertility specialist to discuss fertility preservation and reproductive options.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Imaging studies where clinically appropriate (eg, cranial magnetic resonance imaging if there are persistent or especially recent-onset seizures, focal neurologic signs such as weakness or a visual field defect, or symptoms such as diplopia or headache that may signal the presence of meningioma or atherosclerotic cerebrovascular disease).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2356213971">
         <span class="h2">
          Prevention of complications
         </span>
         <span class="headingEndMark">
          —
         </span>
         The initial clinical evaluation is often the best opportunity to discuss with patients and family members/caregivers the clinical course of WS, practical management and screening issues, and the importance of continued monitoring to identify treatable, potentially life-threatening complications, such as neoplasia or cardiovascular disease. This should include a discussion of primary and secondary prevention measures, including:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Risk assessment and primary prevention of atherosclerotic cardiovascular disease (see
         <a class="medical medical_review" href="/z/d/html/1546.html" rel="external">
          "Atherosclerotic cardiovascular disease risk assessment for primary prevention in adults: Our approach"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/114029.html" rel="external">
          "Cardiovascular disease risk assessment for primary prevention: Risk calculators"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7573.html" rel="external">
          "Overview of primary prevention of cardiovascular disease"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Smoking avoidance or cessation (see
         <a class="medical medical_review" href="/z/d/html/16634.html" rel="external">
          "Overview of smoking cessation management in adults"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Regular exercise to maintain weight, counter sarcopenia, and aid in the control of diabetes mellitus, hyperlipidemia, and hypertension
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Use of protective clothing and sunscreen to prevent skin cancer (see
         <a class="medical medical_review" href="/z/d/html/128194.html" rel="external">
          "Cutaneous squamous cell carcinoma: Primary and secondary prevention"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4842.html" rel="external">
          "Primary prevention of melanoma"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/13751.html" rel="external">
          "Selection of sunscreen and sun-protective measures"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Careful, continuous skin care to avoid, detect, and aggressively treat skin ulcers (see
         <a class="medical medical_review" href="/z/d/html/99040.html" rel="external">
          "Overview of treatment of chronic wounds"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prevention of falls resulting in fractures (eg, adding grab bars in the shower, wearing shoes with good traction, eliminating tripping hazards, providing adequate lighting) (see
         <a class="medical medical_review" href="/z/d/html/3014.html" rel="external">
          "Falls: Prevention in community-dwelling older persons"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Screening/surveillance for the most common cancers associated with WS (eg, osteosarcomas, melanoma, and thyroid carcinoma), as well as for other types of cancer that have been reported in patients with WS, though not at apparent elevated rates (
         <a class="graphic graphic_table graphicRef132650" href="/z/d/graphic/132650.html" rel="external">
          table 1
         </a>
         ) (see
         <a class="local">
          'Cancer surveillance'
         </a>
         below)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1128198837">
         <span class="h2">
          Clinical management
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical management of patients with WS involves addressing immediate concerns (eg, planning surgery for ocular cataracts) and providing appropriate treatment for common complications of WS, such as diabetes mellitus, hypertension, dyslipidemia, osteoporosis, skin ulcerations, soft tissue calcification, and cancer [
         <a href="#rid33">
          33,34,54-58,60-62
         </a>
         ]. A detailed discussion of treatments for these conditions is beyond the scope of this review but can be found elsewhere in UpToDate.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diabetes mellitus
         </strong>
         – Diabetes associated with WS is characterized by marked insulin resistance [
         <a href="#rid55">
          55
         </a>
         ]. Oral agents, such as thiazolidinediones and
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         , have been used with benefit for glycemic control. (See
         <a class="medical medical_review" href="/z/d/html/1757.html" rel="external">
          "Thiazolidinediones in the treatment of type 2 diabetes mellitus"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1779.html" rel="external">
          "Initial management of hyperglycemia in adults with type 2 diabetes mellitus"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dyslipidemia
         </strong>
         – Most patients with WS have hypertriglyceridemia and/or elevated levels of low-density lipoprotein (LDL) cholesterol and low levels of high-density lipoprotein (HDL) cholesterol. Statin treatment has been successfully used in patients with WS to achieve target values of lipid levels [
         <a href="#rid63">
          63
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4549.html" rel="external">
          "Low-density lipoprotein cholesterol-lowering therapy in the primary prevention of cardiovascular disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4564.html" rel="external">
          "Statins: Actions, side effects, and administration"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Osteoporosis
         </strong>
         – Bisphosphonates have been widely used for the treatment of osteoporosis in WS [
         <a href="#rid56">
          56
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2030.html" rel="external">
          "Bisphosphonate therapy for the treatment of osteoporosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Skin ulcers
         </strong>
         – Chronic skin ulcers of the lower legs and feet in patients with WS are an important source of morbidity and are difficult to treat. Management may involve surgical debridement and curettage, use of topical preparations and special dressings, control of infection and pain, dermis matrix substitutes, and negative pressure wound therapy [
         <a href="#rid33">
          33,34
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/99040.html" rel="external">
          "Overview of treatment of chronic wounds"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/118064.html" rel="external">
          "Skin substitutes"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2881.html" rel="external">
          "Negative pressure wound therapy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1588884883">
         <span class="h2">
          Fertility issues
         </span>
         <span class="headingEndMark">
          —
         </span>
         The initial or subsequent follow-up visits provide an opportunity to discuss fertility issues as well as counsel family members regarding their
         <em>
          WRN
         </em>
         carrier status and disease risk. Males and females with WS are fertile, with variable, apparently rapid loss of fertility over time. This issue was initially quantified in 125 patients with WS, who had a net fertility of 0.4 children per patient (or 1.1 children per known married patient) [
         <a href="#rid28">
          28
         </a>
         ]. Nineteen females included in this series reported at least 53 pregnancies, with 10 giving birth to 30 children who survived the perinatal period. The other 23 known pregnancies ended either in abortions, stillbirths, premature deliveries, or deaths at delivery.
        </p>
        <p>
         Reduced fertility in patients with WS may reflect a combination of hypogonadism, reduced sperm viability and counts, and inability to conceive or carry pregnancies to live births. Preterm deliveries have been reported and attributed to cervical incompetence [
         <a href="#rid64">
          64
         </a>
         ], and preeclampsia has been noted as an obstetric complication.
        </p>
        <p class="headingAnchor" id="H1247608571">
         <span class="h2">
          Cancer surveillance
         </span>
         <span class="headingEndMark">
          —
         </span>
         Many different histologic types of cancer have been identified in patients with WS [
         <a href="#rid35">
          35
         </a>
         ]. Among these, a small subset of "elevated risk" cancer types account for two-thirds of cancer reports in patients with WS (
         <a class="graphic graphic_table graphicRef132650" href="/z/d/graphic/132650.html" rel="external">
          table 1
         </a>
         ). In descending frequency, these elevated risk cancer types are thyroid epithelial neoplasms, melanoma, meningiomas, soft tissue sarcomas, leukemia and preleukemic conditions, and osteosarcoma (
         <a class="graphic graphic_table graphicRef132650" href="/z/d/graphic/132650.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
         Annual screening for thyroid cancer by ultrasound is recommended, given the elevated risk in individuals with WS [
         <a href="#rid65">
          65
         </a>
         ], as well as annual total body skin examination for the early detection of melanoma, with attention to the nasal mucosa, nail beds, palms, and soles.
        </p>
        <p class="headingAnchor" id="H298575863">
         <span class="h2">
          Genetic counseling
         </span>
         <span class="headingEndMark">
          —
         </span>
         Genetic counseling may be useful for many patients with WS to clarify the nature and inheritance of WS; explain molecular diagnosis testing results and options; and discuss practical issues, such as the probability of reproductive success and associated risks. Parents and offspring of patients with WS are obligate heterozygote carriers of one
         <em>
          WRN
         </em>
         pathogenic, variant allele, though they do not appear to be at elevated risk of developing clinical findings of WS or associated disorders. Siblings
         <strong>
         </strong>
         of affected patients have a 25 percent likelihood of being affected themselves, a 50 percent chance of carrying a single
         <em>
          WRN
         </em>
         pathogenic allele, and a 25 percent chance of being both unaffected and not a carrier [
         <a href="#rid2">
          2
         </a>
         ]. Referral to a genetics professional is recommended for family members who are or at risk to be heterozygous carriers, so that they can be counseled regarding carrier testing for their partners and reproductive options.
        </p>
        <p class="headingAnchor" id="H1446587709">
         <span class="h2">
          Investigational therapies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several pharmacologic agents have been investigated in vitro or in animal models for their potential to delay the onset or progression of WS signs and symptoms. Examples include vitamin C [
         <a href="#rid66">
          66-69
         </a>
         ], p38 mitogen-activated protein kinase (MAPK)
         <strong>
         </strong>
         inhibitors [
         <a href="#rid70">
          70-73
         </a>
         ],
         <a class="drug drug_general" data-topicid="9696" href="/z/d/drug information/9696.html" rel="external">
          nicotinamide
         </a>
         in the form of nicotinamide adenine dinucleotide (NAD+) [
         <a href="#rid74">
          74
         </a>
         ], and the mammalian (mechanistic) target of rapamycin (mTOR) inhibitors
         <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">
          sirolimus
         </a>
         and
         <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">
          everolimus
         </a>
         [
         <a href="#rid75">
          75
         </a>
         ].
        </p>
        <p>
         Among pathogenic
         <em>
          WRN
         </em>
         variants, very few appear to be good candidates for mutation-specific therapies, such as exon skipping or stop codon readthrough [
         <a href="#rid4">
          4
         </a>
         ]. One cell line from a patient with WS with a newly reported
         <em>
          WRN
         </em>
         stop codon variant (c.3767C&gt;G) re-expressed modest levels of full-length WRN protein after being treated with aminoglycosides and ataluren to promote stop codon readthrough [
         <a href="#rid76">
          76
         </a>
         ]. Approximately two-thirds of pathogenic
         <em>
          WRN
         </em>
         variants are single base substitutions and, therefore, may be good candidates for in vivo base editing or other types of corrective genome engineering.
        </p>
        <p class="headingAnchor" id="H560517021">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Active clinical management to detect, treat, or prevent common clinical problems that contribute to morbidity and early mortality in many patients with Werner syndrome (WS) allows them to lead longer and productive lives. The median age of death is approximately 54 years [
         <a href="#rid53">
          53,77
         </a>
         ]. Cancer and myocardial infarction have been the main causes of death [
         <a href="#rid53">
          53
         </a>
         ]. However, a retrospective study from 2011 to 2020 of Japanese patients with WS reported a mean age at death of 59 years, a four- to seven-year increase in life span [
         <a href="#rid78">
          78
         </a>
         ]. Epithelial and nonepithelial malignancies remained the leading causes of death, followed by infection, with no reported deaths from cardiovascular diseases.
        </p>
        <p class="headingAnchor" id="H3732562479">
         <span class="h1">
          ONLINE RESOURCES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Online information on Werner syndrome (WS) can be found at:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdlmp.uw.edu%2Fresearch-center%2Fwerner%2Fregistry%2Fregistry.html&amp;token=zpNCX14A2R12bA0oIWem40juL9ratCrV9tXnJsNS8hqHuegyQFRcMHAS6777cZiW%2BEk8X9q8XiI1DeTPWXUQaa8AtSQsFLDSFqHlsS1NKKs%3D&amp;TOPIC_ID=106742" target="_blank">
          International Registry of Werner Syndrome
         </a>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.pathology.washington.edu%2Fresearch%2Fwerner%2Fdatabase%2F&amp;token=v0N5%2F2Hnwg65r0lfZlbF3TPQFTj9LG%2B7bfy%2FYO0mf4IW%2F%2BCancsZsOMaqm8SX11s44chtUbQL%2BbIGwNjK%2Fsycw%3D%3D&amp;TOPIC_ID=106742" target="_blank">
          WRN Locus-Specific Mutational Database
         </a>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Frarediseases.org%2Frare-diseases%2Fwerner-syndrome%2F&amp;token=9E9IX7kiH9qRiTPgEvfhBXfzSfVr6Je40Jo5pwBzJ8VmUzqG9H3mqEGIA46sZUqZXG4hdUURi1l8ofjRYjNFig%3D%3D&amp;TOPIC_ID=106742" target="_blank">
          National Organization for Rare Disorders (NORD)
         </a>
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2157023411">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiology and pathogenesis
         </strong>
         – Werner syndrome (WS) is a rare, autosomal recessive disorder caused by biallelic, pathogenic variants in the
         <em>
          WRN
         </em>
         gene encoding a RECQ helicase protein involved in DNA replication, recombination, and repair. The incidence is 1 per 10,000 to &lt;1 per 100,000 births and is highest in Japan, Sardinia, India, and Pakistan due to the presence of common local pathogenic founder variants. (See
         <a class="local">
          'Epidemiology'
         </a>
         above and
         <a class="local">
          'Pathophysiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical features
         </strong>
         – WS is characterized by short stature and the appearance in adolescence or early adulthood of premature graying and loss of hair; progressive sharpening of facial features, with "beaked" or "bird-like" appearance (
         <a class="graphic graphic_picture graphicRef132645" href="/z/d/graphic/132645.html" rel="external">
          picture 1
         </a>
         ); bilateral cataracts; high-pitched voice; scleroderma-like skin changes with ulcerations of feet and ankles (
         <a class="graphic graphic_picture graphicRef132648" href="/z/d/graphic/132648.html" rel="external">
          picture 2
         </a>
         ); and a characteristic calcification of soft tissue and tendons (
         <a class="graphic graphic_diagnosticimage graphicRef133224" href="/z/d/graphic/133224.html" rel="external">
          image 1
         </a>
         ). Patients with WS have earlier onset of clinically important, age-related diseases, including atherosclerosis, diabetes mellitus, osteoporosis, and some cancers (
         <a class="graphic graphic_table graphicRef132650" href="/z/d/graphic/132650.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Clinical features'
         </a>
         above and
         <a class="local">
          'Risk of cancer'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – The diagnosis of WS is based on characteristic clinical features that together are diagnostic, though they may be difficult to assess or absent in young individuals. Cardinal signs of WS include (
         <a class="graphic graphic_table graphicRef132672" href="/z/d/graphic/132672.html" rel="external">
          table 2
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Premature graying and/or thinning of scalp hair
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Bilateral cataract
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Scleroderma-like skin changes, intractable lower leg skin ulcers
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Soft tissue calcification (Achilles tendon)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Bird-like face
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         High-pitched voice
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The identification of causative pathogenic variants in both copies of the
         <em>
          WRN
         </em>
         gene by molecular genetic testing confirms the diagnosis. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management
         </strong>
         – There is no specific or effective therapy for WS. Because of the multisystem nature of WS, patients should be managed in medical centers with expertise in rare, complex diseases and ready access to multiple specialty consultation. Pharmacologic management of hypertension, diabetes mellitus, and lipid metabolic abnormalities; surgical removal of cataracts; aggressive treatment of skin ulcers; and screening for cancer or other acquired diseases are the mainstays of management. (See
         <a class="local">
          'Management'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Oshima J, Sidorova JM, Monnat RJ Jr. Werner syndrome: Clinical features, pathogenesis and potential therapeutic interventions. Ageing Res Rev 2017; 33:105.
          </a>
         </li>
         <li class="breakAll">
          Oshima J, Martin GM, Hisama FM. Werner syndrome. In: GeneReviews, Adam MP, Ardinger HH, Pagon RA, et al (Eds), University of Washington, Seattle, 1993.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saha B, Lessel D, Nampoothiri S, et al. Ethnic-Specific WRN Mutations in South Asian Werner Syndrome Patients: Potential Founder Effect in Patients with Indian or Pakistani Ancestry. Mol Genet Genomic Med 2013; 1:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fu W, Ligabue A, Rogers KJ, et al. Human RECQ Helicase Pathogenic Variants, Population Variation and "Missing" Diseases. Hum Mutat 2017; 38:193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yu CE, Oshima J, Fu YH, et al. Positional cloning of the Werner's syndrome gene. Science 1996; 272:258.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Croteau DL, Popuri V, Opresko PL, Bohr VA. Human RecQ helicases in DNA repair, recombination, and replication. Annu Rev Biochem 2014; 83:519.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karczewski KJ, Francioli LC, Tiao G, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature 2020; 581:434.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lek M, Karczewski KJ, Minikel EV, et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature 2016; 536:285.
          </a>
         </li>
         <li class="breakAll">
          Schellenberg GD, Miki T, Yu CE, Nakura J. Werner syndrome. In: Online Metabolic and Molecular Basis of Inherited Disease, Valle D, Beaudet AL, Vogelstein B, et al (Eds), McGraw-Hill, 2019.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Satoh M, Imai M, Sugimoto M, et al. Prevalence of Werner's syndrome heterozygotes in Japan. Lancet 1999; 353:1766.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Masala MV, Scapaticci S, Olivieri C, et al. Epidemiology and clinical aspects of Werner's syndrome in North Sardinia: description of a cluster. Eur J Dermatol 2007; 17:213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Friedrich K, Lee L, Leistritz DF, et al. WRN mutations in Werner syndrome patients: genomic rearrangements, unusual intronic mutations and ethnic-specific alterations. Hum Genet 2010; 128:103.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yokote K, Chanprasert S, Lee L, et al. WRN Mutation Update: Mutation Spectrum, Patient Registries, and Translational Prospects. Hum Mutat 2017; 38:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tang W, Robles AI, Beyer RP, et al. The Werner syndrome RECQ helicase targets G4 DNA in human cells to modulate transcription. Hum Mol Genet 2016; 25:2060.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moser MJ, Kamath-Loeb AS, Jacob JE, et al. WRN helicase expression in Werner syndrome cell lines. Nucleic Acids Res 2000; 28:648.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Swanson C, Saintigny Y, Emond MJ, Monnat RJ Jr. The Werner syndrome protein has separable recombination and survival functions. DNA Repair (Amst) 2004; 3:475.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kamath-Loeb AS, Welcsh P, Waite M, et al. The enzymatic activities of the Werner syndrome protein are disabled by the amino acid polymorphism R834C. J Biol Chem 2004; 279:55499.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kamath-Loeb AS, Zavala-van Rankin DG, Flores-Morales J, et al. Homozygosity for the WRN Helicase-Inactivating Variant, R834C, does not confer a Werner syndrome clinical phenotype. Sci Rep 2017; 7:44081.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tokita M, Kennedy SR, Risques RA, et al. Werner syndrome through the lens of tissue and tumour genomics. Sci Rep 2016; 6:32038.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chan EM, Shibue T, McFarland JM, et al. WRN helicase is a synthetic lethal target in microsatellite unstable cancers. Nature 2019; 568:551.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lieb S, Blaha-Ostermann S, Kamper E, et al. Werner syndrome helicase is a selective vulnerability of microsatellite instability-high tumor cells. Elife 2019; 8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kategaya L, Perumal SK, Hager JH, Belmont LD. Werner Syndrome Helicase Is Required for the Survival of Cancer Cells with Microsatellite Instability. iScience 2019; 13:488.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Wietmarschen N, Sridharan S, Nathan WJ, et al. Repeat expansions confer WRN dependence in microsatellite-unstable cancers. Nature 2020; 586:292.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sommers JA, Kulikowicz T, Croteau DL, et al. A high-throughput screen to identify novel small molecule inhibitors of the Werner Syndrome Helicase-Nuclease (WRN). PLoS One 2019; 14:e0210525.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aggarwal M, Sommers JA, Shoemaker RH, Brosh RM Jr. Inhibition of helicase activity by a small molecule impairs Werner syndrome helicase (WRN) function in the cellular response to DNA damage or replication stress. Proc Natl Acad Sci U S A 2011; 108:1525.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Picco G, Cattaneo CM, van Vliet EJ, et al. Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repair-Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and Immunotherapy. Cancer Discov 2021; 11:1923.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oshima J, Hisama FM. Search and insights into novel genetic alterations leading to classical and atypical Werner syndrome. Gerontology 2014; 60:239.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Epstein CJ, Martin GM, Schultz AL, Motulsky AG. Werner's syndrome a review of its symptomatology, natural history, pathologic features, genetics and relationship to the natural aging process. Medicine (Baltimore) 1966; 45:177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goto M. Clinical characteristics of Werner syndrome and other premature aging syndromes: pattern of aging in progeroid syndromes. Gann Monograph Cancer Res 2001; 49:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tollefsbol TO, Cohen HJ. Werner's syndrome: an underdiagnosed disorder resembling premature aging. Age 1984; 7:75.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goto M. Werner's syndrome: from clinics to genetics. Clin Exp Rheumatol 2000; 18:760.
          </a>
         </li>
         <li class="breakAll">
          Hatamochi A. Dermatological features and collagen metabolism in Werner syndrome. In: Premature Gray Hair to Helicase-Werner Syndrome: Implications for Aging and Cancer, 1st ed, Goto M, Miller RW (Eds), Karger Publishers, 2001. p.51.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kubota Y, Takemoto M, Taniguchi T, et al. Management guideline for Werner syndrome 2020. 6. Skin ulcers associated with Werner syndrome: Prevention and non-surgical and surgical treatment. Geriatr Gerontol Int 2021; 21:153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Motegi SI, Takemoto M, Taniguchi T, et al. Management guideline for Werner syndrome 2020. 7. Skin ulcer associated with Werner syndrome: Dermatological treatment. Geriatr Gerontol Int 2021; 21:160.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lauper JM, Krause A, Vaughan TL, Monnat RJ Jr. Spectrum and risk of neoplasia in Werner syndrome: a systematic review. PLoS One 2013; 8:e59709.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Onishi S, Takemoto M, Ishikawa T, et al. Japanese diabetic patients with Werner syndrome exhibit high incidence of cancer. Acta Diabetol 2012; 49 Suppl 1:S259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lauper JM, Monnat RJ Jr. Diabetes mellitus and cancer in Werner syndrome. Acta Diabetol 2014; 51:159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kadowaki Y, Kodama S, Moriyama M, Suzuki M. The Relationship between Werner Syndrome and Sinonasal Malignant Melanoma: Two Sibling Cases of Werner Syndrome with Malignant Melanoma. Case Rep Otolaryngol 2017; 2017:9361612.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koshizaka M, Maezawa Y, Maeda Y, et al. Time gap between the onset and diagnosis in Werner syndrome: a nationwide survey and the 2020 registry in Japan. Aging (Albany NY) 2020; 12:24940.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Takemoto M, Mori S, Kuzuya M, et al. Diagnostic criteria for Werner syndrome based on Japanese nationwide epidemiological survey. Geriatr Gerontol Int 2013; 13:475.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen L, Lee L, Kudlow BA, et al. LMNA mutations in atypical Werner's syndrome. Lancet 2003; 362:440.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weedon MN, Ellard S, Prindle MJ, et al. An in-frame deletion at the polymerase active site of POLD1 causes a multisystem disorder with lipodystrophy. Nat Genet 2013; 45:947.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lessel D, Hisama FM, Szakszon K, et al. POLD1 Germline Mutations in Patients Initially Diagnosed with Werner Syndrome. Hum Mutat 2015; 36:1070.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garavelli L, D'Apice MR, Rivieri F, et al. Mandibuloacral dysplasia type A in childhood. Am J Med Genet A 2009; 149A:2258.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barrowman J, Hamblet C, Kane MS, Michaelis S. Requirements for efficient proteolytic cleavage of prelamin A by ZMPSTE24. PLoS One 2012; 7:e32120.
          </a>
         </li>
         <li class="breakAll">
          Gordon LB, Brown WT, Collins FS. Hutchinson-Gilford progeria syndrome. In: GeneReviews, Adam MP, Ardinger HH, Pagon RA, et al (Eds), University of Washington, Seattle, 1993.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eriksson M, Brown WT, Gordon LB, et al. Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. Nature 2003; 423:293.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flynn P, Aird RB. A neuroectodermal syndrome of dominant inheritance. J Neurol Sci 1965; 2:161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Milunsky JM, Maher TA, Zhao G, et al. TFAP2A mutations result in branchio-oculo-facial syndrome. Am J Hum Genet 2008; 82:1171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Avila M, Dyment DA, Sagen JV, et al. Clinical reappraisal of SHORT syndrome with PIK3R1 mutations: toward recommendation for molecular testing and management. Clin Genet 2016; 89:501.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carbone M, Arron ST, Beutler B, et al. Tumour predisposition and cancer syndromes as models to study gene-environment interactions. Nat Rev Cancer 2020; 20:533.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oshima J, Kato H, Maezawa Y, Yokote K. RECQ helicase disease and related progeroid syndromes: RECQ2018 meeting. Mech Ageing Dev 2018; 173:80.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goto M, Ishikawa Y, Sugimoto M, Furuichi Y. Werner syndrome: a changing pattern of clinical manifestations in Japan (1917~2008). Biosci Trends 2013; 7:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuzuya M, Takemoto M, Kubota Y, et al. Management guideline for Werner syndrome 2020. 2. Sarcopenia associated with Werner syndrome. Geriatr Gerontol Int 2021; 21:139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Takemoto M, Kubota Y, Taniguchi T, et al. Management guideline for Werner syndrome 2020. 3. Diabetes associated with Werner syndrome. Geriatr Gerontol Int 2021; 21:142.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mori S, Takemoto M, Kubota Y, et al. Management guideline for Werner syndrome 2020. 4. Osteoporosis associated with Werner syndrome. Geriatr Gerontol Int 2021; 21:146.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taniguchi T, Takemoto M, Kubota Y, et al. Management guideline for Werner syndrome 2020. 5. Infection associated with Werner syndrome. Geriatr Gerontol Int 2021; 21:150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taniguchi A, Tanaka Y, Takemoto M, et al. Management guideline for Werner syndrome 2020 8. Calcification in tendons associated with Werner syndrome. Geriatr Gerontol Int 2021; 21:163.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lyons C, Gallagher D, McSwiney T, et al. The ophthalmic diagnosis and management of four siblings with Werner syndrome. Int Ophthalmol 2019; 39:1371.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yeong EK, Yang CC. Chronic leg ulcers in Werner's syndrome. Br J Plast Surg 2004; 57:86.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matucci-Cerinic M, Denton CP, Furst DE, et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 2011; 70:32.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Noda S, Asano Y, Masuda S, et al. Bosentan: a novel therapy for leg ulcers in Werner syndrome. J Am Acad Dermatol 2011; 65:e54.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsukamoto K, Takemoto M, Kubota Y, et al. Management guideline for Werner syndrome 2020 1. Dyslipidemia and fatty liver associated with Werner syndrome. Geriatr Gerontol Int 2021; 21:133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sołek-Pastuszka J, Zagrodnik-Ułan E, Płonka T, et al. Pregnancy complicated by Werner syndrome. Acta Obstet Gynecol Scand 2011; 90:201.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walsh MF, Chang VY, Kohlmann WK, et al. Recommendations for Childhood Cancer Screening and Surveillance in DNA Repair Disorders. Clin Cancer Res 2017; 23:e23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aumailley L, Lebel M. The Impact of Vitamin C on Different System Models of Werner Syndrome. Antioxid Redox Signal 2021; 34:856.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aumailley L, Roux-Dalvai F, Kelly I, et al. Vitamin C alters the amount of specific endoplasmic reticulum associated proteins involved in lipid metabolism in the liver of mice synthesizing a nonfunctional Werner syndrome (Wrn) mutant protein. PLoS One 2018; 13:e0193170.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aumailley L, Dubois MJ, Brennan TA, et al. Serum vitamin C levels modulate the lifespan and endoplasmic reticulum stress response pathways in mice synthesizing a nonfunctional mutant WRN protein. FASEB J 2018; 32:3623.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Massip L, Garand C, Paquet ER, et al. Vitamin C restores healthy aging in a mouse model for Werner syndrome. FASEB J 2010; 24:158.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Freund A, Patil CK, Campisi J. p38MAPK is a novel DNA damage response-independent regulator of the senescence-associated secretory phenotype. EMBO J 2011; 30:1536.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davis T, Brook AJ, Rokicki MJ, et al. Evaluating the Role of p38 MAPK in the Accelerated Cell Senescence of Werner Syndrome Fibroblasts. Pharmaceuticals (Basel) 2016; 9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davis T, Rokicki MJ, Bagley MC, Kipling D. The effect of small-molecule inhibition of MAPKAPK2 on cell ageing phenotypes of fibroblasts from human Werner syndrome. Chem Cent J 2013; 7:18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davis T, Baird DM, Haughton MF, et al. Prevention of accelerated cell aging in Werner syndrome using a p38 mitogen-activated protein kinase inhibitor. J Gerontol A Biol Sci Med Sci 2005; 60:1386.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fang EF, Hou Y, Lautrup S, et al. NAD+ augmentation restores mitophagy and limits accelerated aging in Werner syndrome. Nat Commun 2019; 10:5284.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saha B, Cypro A, Martin GM, Oshima J. Rapamycin decreases DNA damage accumulation and enhances cell growth of WRN-deficient human fibroblasts. Aging Cell 2014; 13:573.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agrelo R, Sutz MA, Setien F, et al. A novel Werner Syndrome mutation: pharmacological treatment by read-through of nonsense mutations and epigenetic therapies. Epigenetics 2015; 10:329.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huang S, Lee L, Hanson NB, et al. The spectrum of WRN mutations in Werner syndrome patients. Hum Mutat 2006; 27:558.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kato H, Koshizaka M, Kaneko H, et al. Lifetime extension and the recent cause of death in Werner syndrome: a retrospective study from 2011 to 2020. Orphanet J Rare Dis 2022; 17:226.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 106742 Version 2.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26993153" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Werner syndrome: Clinical features, pathogenesis and potential therapeutic interventions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26993153" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Werner syndrome: Clinical features, pathogenesis and potential therapeutic interventions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23936869" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Ethnic-Specific WRN Mutations in South Asian Werner Syndrome Patients: Potential Founder Effect in Patients with Indian or Pakistani Ancestry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27859906" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Human RECQ Helicase Pathogenic Variants, Population Variation and "Missing" Diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8602509" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Positional cloning of the Werner's syndrome gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24606147" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Human RecQ helicases in DNA repair, recombination, and replication.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32461654" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : The mutational constraint spectrum quantified from variation in 141,456 humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27535533" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Analysis of protein-coding genetic variation in 60,706 humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27535533" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Analysis of protein-coding genetic variation in 60,706 humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10347997" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Prevalence of Werner's syndrome heterozygotes in Japan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17478382" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Epidemiology and clinical aspects of Werner's syndrome in North Sardinia: description of a cluster.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20443122" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : WRN mutations in Werner syndrome patients: genomic rearrangements, unusual intronic mutations and ethnic-specific alterations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27667302" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : WRN Mutation Update: Mutation Spectrum, Patient Registries, and Translational Prospects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26984941" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : The Werner syndrome RECQ helicase targets G4 DNA in human cells to modulate transcription.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10606667" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : WRN helicase expression in Werner syndrome cell lines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15084309" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : The Werner syndrome protein has separable recombination and survival functions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15489508" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : The enzymatic activities of the Werner syndrome protein are disabled by the amino acid polymorphism R834C.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28276523" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Homozygosity for the WRN Helicase-Inactivating Variant, R834C, does not confer a Werner syndrome clinical phenotype.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27559010" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Werner syndrome through the lens of tissue and tumour genomics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30971823" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : WRN helicase is a synthetic lethal target in microsatellite unstable cancers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30910006" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Werner syndrome helicase is a selective vulnerability of microsatellite instability-high tumor cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30898619" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Werner Syndrome Helicase Is Required for the Survival of Cancer Cells with Microsatellite Instability.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32999459" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Repeat expansions confer WRN dependence in microsatellite-unstable cancers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30625228" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : A high-throughput screen to identify novel small molecule inhibitors of the Werner Syndrome Helicase-Nuclease (WRN).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21220316" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Inhibition of helicase activity by a small molecule impairs Werner syndrome helicase (WRN) function in the cellular response to DNA damage or replication stress.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33837064" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repair-Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and Immunotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24401204" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Search and insights into novel genetic alterations leading to classical and atypical Werner syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5327241" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Werner's syndrome a review of its symptomatology, natural history, pathologic features, genetics and relationship to the natural aging process.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Clinical characteristics of Werner syndrome and other premature aging syndromes: pattern of aging in progeroid syndromes
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Werner's syndrome: an underdiagnosed disorder resembling premature aging
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11138345" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Werner's syndrome: from clinics to genetics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11138345" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Werner's syndrome: from clinics to genetics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33225552" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Management guideline for Werner syndrome 2020. 6. Skin ulcers associated with Werner syndrome: Prevention and non-surgical and surgical treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33142357" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Management guideline for Werner syndrome 2020. 7. Skin ulcer associated with Werner syndrome: Dermatological treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23573208" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Spectrum and risk of neoplasia in Werner syndrome: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22872450" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Japanese diabetic patients with Werner syndrome exhibit high incidence of cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23386316" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Diabetes mellitus and cancer in Werner syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28717528" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : The Relationship between Werner Syndrome and Sinonasal Malignant Melanoma: Two Sibling Cases of Werner Syndrome with Malignant Melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33373317" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Time gap between the onset and diagnosis in Werner syndrome: a nationwide survey and the 2020 registry in Japan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22817610" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Diagnostic criteria for Werner syndrome based on Japanese nationwide epidemiological survey.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12927431" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : LMNA mutations in atypical Werner's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23770608" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : An in-frame deletion at the polymerase active site of POLD1 causes a multisystem disorder with lipodystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26172944" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : POLD1 Germline Mutations in Patients Initially Diagnosed with Werner Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19764019" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Mandibuloacral dysplasia type A in childhood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22355414" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Requirements for efficient proteolytic cleavage of prelamin A by ZMPSTE24.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22355414" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Requirements for efficient proteolytic cleavage of prelamin A by ZMPSTE24.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12714972" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5878601" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : A neuroectodermal syndrome of dominant inheritance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18423521" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : TFAP2A mutations result in branchio-oculo-facial syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26497935" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Clinical reappraisal of SHORT syndrome with PIK3R1 mutations: toward recommendation for molecular testing and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32472073" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Tumour predisposition and cancer syndromes as models to study gene-environment interactions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29752965" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : RECQ helicase disease and related progeroid syndromes: RECQ2018 meeting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23524889" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Werner syndrome: a changing pattern of clinical manifestations in Japan (1917~2008).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33169468" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Management guideline for Werner syndrome 2020. 2. Sarcopenia associated with Werner syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33169495" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Management guideline for Werner syndrome 2020. 3. Diabetes associated with Werner syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33155383" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Management guideline for Werner syndrome 2020. 4. Osteoporosis associated with Werner syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33135262" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Management guideline for Werner syndrome 2020. 5. Infection associated with Werner syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33260264" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Management guideline for Werner syndrome 2020 8. Calcification in tendons associated with Werner syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29705892" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : The ophthalmic diagnosis and management of four siblings with Werner syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14672683" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Chronic leg ulcers in Werner's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20805294" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21763553" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Bosentan: a novel therapy for leg ulcers in Werner syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33258561" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Management guideline for Werner syndrome 2020 1. Dyslipidemia and fatty liver associated with Werner syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21241272" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Pregnancy complicated by Werner syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28572264" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Recommendations for Childhood Cancer Screening and Surveillance in DNA Repair Disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33202145" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : The Impact of Vitamin C on Different System Models of Werner Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29494634" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Vitamin C alters the amount of specific endoplasmic reticulum associated proteins involved in lipid metabolism in the liver of mice synthesizing a nonfunctional Werner syndrome (Wrn) mutant protein.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29452565" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Serum vitamin C levels modulate the lifespan and endoplasmic reticulum stress response pathways in mice synthesizing a nonfunctional mutant WRN protein.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19741171" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Vitamin C restores healthy aging in a mouse model for Werner syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21399611" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : p38MAPK is a novel DNA damage response-independent regulator of the senescence-associated secretory phenotype.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27136566" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Evaluating the Role of p38 MAPK in the Accelerated Cell Senescence of Werner Syndrome Fibroblasts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23360642" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : The effect of small-molecule inhibition of MAPKAPK2 on cell ageing phenotypes of fibroblasts from human Werner syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16339323" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Prevention of accelerated cell aging in Werner syndrome using a p38 mitogen-activated protein kinase inhibitor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31754102" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : NAD+ augmentation restores mitophagy and limits accelerated aging in Werner syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24308646" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Rapamycin decreases DNA damage accumulation and enhances cell growth of WRN-deficient human fibroblasts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25830902" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : A novel Werner Syndrome mutation: pharmacological treatment by read-through of nonsense mutations and epigenetic therapies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16673358" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : The spectrum of WRN mutations in Werner syndrome patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35698103" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Lifetime extension and the recent cause of death in Werner syndrome: a retrospective study from 2011 to 2020.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
